Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MacroH2A.2 is a member of the histone H2A family encoded by the MACROH2A2 gene (H2AFY2), distinguished by its tripartite structure: a histone fold, an intrinsically disordered linker, and a unique globular macrodomain[4]. It integrates into nucleosomes in place of conventional H2A, reducing transcription and contributing to stable gene silencing, including X chromosome inactivation[2]. MacroH2A variants—including MacroH2A.2—are essential for maintaining higher-order chromatin architecture, stabilizing differentiated cellular states, and suppressing transcriptional noise[3][4]. Unlike its paralog macroH2A1.1, which binds to ADP-ribose and can regulate PARP-1 activity, MacroH2A.2’s macrodomain is incompatible with nucleotide binding and does not directly interact with cellular metabolites[1]. Dysregulation of macroH2A histone variants has context-dependent effects in cancer, often acting as tumor suppressors or barriers to cellular reprogramming[4].
Not applicable. No drugs are known to act directly on MacroH2A.2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Core histone macro-H2A.2 (MACROH2A2).